<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K3L4M3" height="0" width="0" style="display:none;visibility:hidden">

Flat White

Questions raised about the Oxford AstraZeneca coronavirus vaccine

1 December 2020

5:31 PM

1 December 2020

5:31 PM

As discussed in this publication by Professor Jennifer Rogers last week, there have been discrepancies in the data reported by AstraZeneca in its trial of the coronavirus vaccine. Professor Rogers noted in particular: 

We are told that one dosing regimen (with a sample size of 2,741 participants) showed efficacy of 90 per cent when the ChAdOx1 nCOV19 vaccine was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (with a sample size of 8,895) showed 62 per cent efficacy when given as two full doses at least one month apart. The

Already a subscriber? Log in

Subscribe for just $2 a week

Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.

  • Unlimited access to spectator.com.au and app
  • The weekly edition on the Spectator Australia app
  • Spectator podcasts and newsletters
  • Full access to spectator.co.uk
Or

Unlock this article

REGISTER


Comments

Don't miss out

Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.

Already a subscriber? Log in

Close